source
- Eli Lilly signs up to $370M ion-channel collaboration with OmniAbEli Lilly has entered a collaboration with antibody platform company OmniAb that could involve up to $370 million in research, development and commercial milestone payments. OmniAb, which was spun…
- MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritisMoonLake Immunotherapeutics said its lead nanobody sonelokimab achieved positive topline results in a phase 3 study of patients with psoriatic arthritis. At week 16, 42.1% of participants reached…